| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 15 | US 10 | 99.56 |
| Renal Diseases and Glomerulopathies | Lifetime | 40 | US 21 | 99.61 |
| Multiple Myeloma Research and Treatments | Lifetime | 70 | US 39 | 99.50 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 373 | US 185 | 98.92 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 154 | US 80 | 98.70 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 57 | US 20 | 97.56 |
| Drug Transport and Resistance Mechanisms | Lifetime | 484 | US 193 | 97.95 |
| Parathyroid Disorders and Treatments | Lifetime | 440 | US 187 | 97.29 |
| Nephrotoxicity and Medicinal Plants | Lifetime | 55 | US 19 | 95.02 |
| Vasculitis and related conditions | Lifetime | 427 | US 119 | 96.21 |
| Dermatological and Skeletal Disorders | Lifetime | 225 | US 80 | 95.54 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 635 | US 236 | 95.62 |
| Complement system in diseases | Lifetime | 731 | US 281 | 94.44 |
| Acute Kidney Injury Research | Lifetime | 719 | US 277 | 93.95 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 29 | US 7 | 99.04 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 19 | US 9 | 99.13 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 61 | US 26 | 99.15 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 215 | US 101 | 97.49 |
| Peptidase Inhibition and Analysis | 2021-2025 | 384 | US 107 | 92.86 |
| Drug Transport and Resistance Mechanisms | 2021-2025 | 244 | US 66 | 88.48 |
| Acute Lymphoblastic Leukemia research | 2021-2025 | 656 | US 301 | 90.95 |
| CNS Lymphoma Diagnosis and Treatment | 2021-2025 | 239 | US 98 | 87.68 |
| Parathyroid Disorders and Treatments | 2021-2025 | 488 | US 129 | 87.00 |
| Vasculitis and related conditions | 2021-2025 | 447 | US 72 | 86.51 |
| Muscle and Compartmental Disorders | 2021-2025 | 128 | US 24 | 81.97 |
| Complement system in diseases | 2021-2025 | 352 | US 89 | 84.06 |
| Acute Kidney Injury Research | 2021-2025 | 541 | US 158 | 83.31 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 201 | US 39 | 73.55 |
| Dermatological and Skeletal Disorders | 2021-2025 | 249 | US 67 | 68.74 |